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Abstract
Introduction: The association of human immunodeficiency virus and immune dysfunction leading to
development of autoimmune markers is well described, but human immunodeficiency virus infection is
relativelyprotectiveforthedevelopmentofsystemiclupuserythematosus.Incontrast,developmentof
systemic lupus erythematosus with hepatitis C and with interferon therapy is well described in a
numberof case reports. Wehere describe thefirst case of systemic lupus erythematosus developing in
a man infected with human immunodeficiency virus, hepatitis C and hepatitis B co-infection where the
onset seems to have been temporally related to interferon therapy.
Case presentation: We report the occurrence of systemic lupus erythematosus complicating
interferon-a therapy for hepatitis C in a 47-year-old asplenic male with haemophilia co-infected with
human immunodeficiency virus and hepatitis B. He presented with a truncal rash, abdominal pains and
headache and later developed grade IV lupus nephritis requiring haemodialysis, mycophenolate
mofetil and steroid therapy. We were able to successfully withdraw dialysis and mycophenolate while
maintaining stable renal function.
Conclusion: Interferon-a is critical in antiviral immunity against hepatitis C but also acts as a
pathogenic mediator for systemic lupus erythematosus, a condition associated with activation of
plasmacytoid dendritic cells that are depleted in human immunodeficiency virus infection. The
occurrence of auto-antibodies and lupus-like features in the coinfections with hepatitis C require
careful assessment. Immunosuppressant therapy for lupus risks exacerbating underlying infections in
patients with concurrent human immunodeficiency virus, hepatitis B and C.
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Co-infection with hepatitis C (HCV) and human immu-
nodeficiency virus (HIV) is a common problem of
increasing clinical significance. Interferon (INF) therapy
is the mainstay of HCV treatment. HCV andHIV have been
associated with the development of autoimmune markers
and disease; INF therapy compounds this risk.
Case presentation
A 47-year-old Caucasian man presented in May 2006 with
abdominal pain, headache for six weeks an undiagnosed
truncal rash for eight months with a background of
haemophilia A (5% factor VIII activity), HIV, Genotype 1b
HCVand HBVcoinfection. His HIV was well-controlled on
lamivudine, tenofovir and ritonavir-boosted lopinavir; his
cluster of differentiation antigen 4+ (CD4+) T-cell count
was 700cells/µL (28%) and he had an undetectable HIV
RNA. He had no prior Acquired Immune Deficiency
Syndrome (AIDS)-defining illnesses. He had compensated
liver cirrhosis (Child Pugh class A, grade 2 inflammation,
stage 4 fibrosis) and had previously failed to achieve HCV
suppression after 19 weeks of pegylated IFN (PEG-IFN)
and ribavarin therapy from March to August 2005. Other
comorbidities include prior traumatic splenectomy in
February 2004, osteoporosis, renal calculi, inactive psor-
iasis and mild obstructive sleep apnoea.
On presentation, he was hypertensive at 200/100 mmHg
without fundoscopic or focal neurological changes. There
were no peripheral stigmata of chronic liver disease.
Investigations on presentation demonstrated new, mildly
increased creatinine 0·13 mmol/L (normal range [NR]
0·06-0·11) but with marked proteinuria 8·79 g/day
(NR<1·5), and a reduced creatinine clearance of 0·94 ml/
sec (NR 1·50-2·50) with dysmorphic red blood cells on
urinalysis. Full blood examination was normal with a
haemoglobin level of 136 g/L, white blood cell count
8·39 × 10
9/L and platelets 173 × 10
9/L. Erythrocyte
sedimentation rate was 103 (NR 1-10), C-reactive peptide
10 (NR 0-5), liver function test showed a low albumin
18 (NR 35-52), normal bilirubin 16 µmol/L (NR <21) and
ALT 26 U/L (NR 0-40), and a slightly raised GGT 83 U/L
(NR 12-64) and ALP 209 U/L (NR <110). The computer
tomography (CT) brain scan was normal, but magnetic
resonance imaging (MRI) showed increased deep white
matter hyperintensities. The electrocardiogram and echo-
cardiogram suggested left ventricular hypertrophy with
normal systolic function. Antineutrophil cytoplasmic
antibodies (ANCA), myeloperoxidase and proteinase-3
antibodies, cryoglobulins, serum protein electrophoresis
and urine Bence Jones proteins were negative. A CT scan of
the abdomen revealed thickened terminal ileum and
moderate ascites. Diagnostic paracentesis revealed a
serum-ascites-albumin gradient of more than 12 which
was non-infective.
Meloxicam and tenofovir were ceased because of worsen-
ing renal function and zidovudine was instituted in place.
Perindopril was commenced at 2 mg, 4 mg then 8 mg and,
later, together with 10mg amlodipine, 12·5 mg hydro-
cholorothiazide and 0·5 mg prazosin twice daily for
control of resistant hypertension.
Antinuclear antibody (ANA), which had formerly been
negative five years prior and weakly positive in 2004
(Figure 1C), was now strongly positive (>1:1280, homo-
geneous) in association with elevated anti-double-
stranded DNA (dsDNA) antibodies (>100), and hypo-
complementemia (C3 0·44 and C4 0·03) consistent with
active systemic lupus erythematosus (SLE). The previous
skin biopsy of the truncal rash, originally thought to be
secondary to a macrolide antibiotic drug reaction, was
reviewed and showed a lichenoid reaction involving hair
follicles without eosinophils, also suggestive of SLE. Renal
biopsy was considered but deferred because of risks
associated with haemophilia. Prednisolone 37·5 mg
daily (0·5 mg/kg, dose adjusted for ritonavir coadminis-
tration) was empirically commenced on 2 June 2006 for
treatment of lupus nephritis.
Further deterioration in renal function to creatinine
0·17 mmol/L and lack of clinical improvement led to a
renal biopsy on 16 June 2006 which revealed class IV
lupus nephritis (Figure 1). Mycophenolate mofetil 1g
twice daily was added on 21 June with clinical improve-
ment and the patient was discharged home on 17 July.
He was readmitted one week later with worsening renal
impairment creatinine 0·26 mmol/L, lethargy, anaemia
and hypotension necessitating cessation of antihyperten-
sives. Pulse methylprednisolone, 500 mg daily for three
days, and intravenous immunoglobulin, 30 g daily, was
started for further renal deterioration. Despite this, urgent
haemodialysis was required on 27 July for marked
acidosis, oliguria and creatinine 0·54 mmol/L. Immuno-
suppression ceased at this time. Further complications
included microangiopathic haemolysis, steroid myopathy,
atrial flutter and spontaneous bacterial peritonitis.
After five months of thrice-weekly haemodialysis, a
dramatic improvement in the patient’s renal function
and proteinuria allowed the successful cessation of
haemodialysis on 26 December 2006.
In May 2007, a gradual rise in ANA, anti-DNA levels and
creatinine were noted necessitating the reinstitution of
mycophenolate 1 g twice daily and prednisolone 40 mg
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20 July 2007 for hepatitis B virus (HBV) treatment.
In November 2007, while on 20 mg prednisolone and
mycophenolate 25 mg twice daily, Coombs-negative
haemolytic anaemia developed, rendering the patient
transfusion-dependent, which improved with darbopoei-
tin-alfa 80 µg weekly. Persistent re-accumulation of ascites
with liver decompensation led to repeated paracentesis
every 2-3 weeks, complicated by further episodes of
peritonitis. His HCV viral load remains high at 2 million
IU but HBV and HIV viral loads remain undetectable with
a CD4 count of 274 (13%). His current creatinine is
maintained between 0·13 and 0·18 mmol/L and pre-
dnisolone has been weaned to 17·5 mg daily and
mycophenolate has been ceased.
Discussion
The occurrence of SLE in the setting of HCV and INF
administration is now well established [1-3] and repre-
sents an accentuation of the underlying cytokine changes
described in SLE pathogenesis [4,5]. Development of SLE
is favoured by both reduced tumour necrosis factor (TNF)
a following anti-TNF therapy or by increased IFNa.I n
coinfected patients, the risk of development of SLE
associated with INFa HCV therapy, HCV is significantly
reduced by the concomitant HIV infection [6].
In HIV, the risk of developing autoantibodies and
autoimmune disease depends on the time in the disease
course and may be stratified by HIV manifestations, CD4
count and HIV viraemia [6]. Autoimmune diseases
predominates in stage 1 (acute HIV) in the setting of
relatively intact host immunity and immune activation,
and in stage 4 with restoration of immune function with
anti-retroviral therapy (ART). The susceptibility of CD4+
CD25+ regulatory T cells to HIV infection [7] and CD4 loss
may both contribute to dysregulation of immune
responses and favour autoimmunity. HIV can increase
autoantibodies through non-specific stimulation of B-cells
[8] and viral and mammalian DNA can trigger toll-like
receptor (TLR) ligation and IFN production by plasmacy-
toid dendritic cells (pDC) [9].
HCV is a potential aetiological factor for SLE and alone can
mimic SLE both clinically and serologically; the presence
of highly specific autoantibodies for SLE such as anti-
Smith, anti-dsDNA and anti-nucleosome antibodies,
distinguishes SLE [2]. In our case, the presence of anti-
dsDNA antibodies, hypocomplementemia and the histo-
logical diagnosis of class IV lupus nephritis established the
diagnosis.
PEG-IFN is commonly associated with development of
autoantibodies and with autoimmune disorders in 4% to
19% of patients, and SLE-like syndromes have been
reported in 0.15% to 0.7% of patients on INF therapy
[1], with the onset ranging from one month to seven years
after INF administration. Most present with arthralgia and
a highly elevated ANA.
Changes in type I IFN levels and pDC redistribution and
activation are important in pathogenesis of SLE [3]. IFN-a
is an autocrine survival factor for pDC that are potent
Figure 1. Patient’s clinical course. A: summary of therapy.
B: serum creatinine. Insert: renal biopsy, haematoxylin and
eosin stain (magnification ×200) and C1q immunoperoxidase
stain (magnification ×400), showing diffuse active lupus
nephritis class IV. Highlighting granular deposits in mesangium
and capillary walls of all immunoglobulins and complements
(“full house immunofluorescence”), distinguishing it from
primary membranoproliferative glomerulonephritis.
C: changes in autoantibodies pattern (Ho, homogenous; Sp,
speckled) and D: complement C3 and C4 (lower limit of
normal for C4 and ref range for C3 are shown). Changes in
anti-DNA antibodies with time. Pred, prednisolone; MMF,
mycophenolate mofetil.
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cells to increase presentation of self-antigens to auto-
reactive T and B cells [10]. In response to viral infection,
pDC further increase IFN production via TLR7 and TLR9
pathways [11], leading to increased pDC migration and
maturation [12].
In this case, IFN therapy was most likely the critical factor
leading to SLE and was temporally related to the
development of the skin rash and evolution of SLE as
demonstrated in Figure 2. HIV infection is protective for
development of SLE [6], and SLE is rare in HCV/HIV
coinfection compared to HCV alone. Depletion of INF-
producing pDCs during HIV infection [13] may contribute
to this protective effect of HIV. DCs can be infected by HIV,
and TLR9 signalling-changes in pDC function may be
reduced indirectly by HIV gp120 [14]. Loss of pDC in HIV
infection usually parallelsthe lossof CD4 [15],but therate
of recovery of DC and CD4 T cells may be independent.
What factors may have been important in the develop-
ment of SLE in this patient at this time? SLE-immune
reconstitution disease was considered; however, there was
no significant change in HIV RNA or CD4+ T-cell count to
precipitate the disease onset, and his ART regime had been
unaltered for more than five years. His peripheral CD4
count (Figure 2) had increased as expected in absolute
numbers following splenectomy in 2004, but CD4
percentage was stable. Normalised pDC numbers expected
with prolonged ART [16,17] may have been permissive for
the IFN-induced development of SLE.
A unique feature of this case was the initial recovery of
renal function despite biopsy-proven class IV SLE nephri-
tis, allowing cessation of dialysis and immunosuppres-
sants. The subsequent decline in renal function with SLE
flare raised the inevitable and vexed issue of further
immunosuppressants; choice, timing and dose. Immuno-
suppressant therapy is a double-edged sword in this
patient with known HIV, HBV and HCV coinfection; his
chronic liver disease only adds to his already significant
infective risk. Immunosuppressant therapy has been
associated with reduced control of HIV [15] and has
been clearly associated with HBV-related flares, reactiva-
tion and mortality. In this case, the HBV viral loads were
well controlled with tenofovir and subsequent switch to
entecavir. The progression of HCV-related liver disease
with immunosuppressants remains unclear, and his viral
load remains high.
In view of his known liver disease and anaemia, we
avoided azathioprine and used mycophenolate and
prednisolone at small ritonavir-boosted doses. The patient
remains on steroid therapy and maintains stable renal
function three months post-cessation of mycophenolate
with reduction in autoantibody levels.
Conclusion
This case report illustrates the complex interactions
between HCV, HIV and SLE and antiviral immunity
mediated by IFNa and pDC. INF therapy is a critical
component of current HCV treatment and its risk
including development of autoantibodies, and autoim-
mune diseases needs to be balanced against its benefits.
The development of autoantibodies and lupus-like fea-
tures in patients with chronic HCV needed careful
assessment and monitoring. The role of immunosuppres-
sants for treatment of autoimmune diseases in the setting
of concomitant HIV, HCV and HBV coinfection is difficult.
Further research into the complex interplay between
immunomodulators and ART in the presence of auto-
immune diseases and viral hepatides is necessary.
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